Products
Semaglutide 5mg/vial | Metabolic Research Peptide
Product Introduction:
Semaglutide Peptide (NN9935) is a synthetic GLP-1 analogue with two amino acid substitutions [Aib(8), Arg(34)] and a Lys26 fatty acid chain, extending its half-life to approximately 7 days and boosting stability. As a GLP-1 receptor agonist, it regulates blood glucose by enhancing insulin secretion and inhibiting glucagon release, while also slowing gastric emptying, curbing appetite and supporting weight loss. These synergistic effects make it a key agent for researching type 2 diabetes, obesity and associated cardiovascular conditions, and it is the well-recognized active ingredient in Ozempic®.
Semaglutide Peptide (NN9935) | CAS: 910463-68-2
Core Specifications
- Peptide Sequence: H-H-Aib-EGTFTSDVSSYLEGQAA-Lys(AEEAc-AEEAc-gammaGlu-17-carboxyheptadecanoyl)-EFIAWLVRGRG-OH
- Net Content: 1.0 mg (AAA) | Purity: >95% (HPLC-MS Verified)
- Counterion: TFA | Format: Freeze-dried in plastic vial
- Chemical Formula: C187H291N45O59 | Avg MW: 4113.64
- CAS No.: 910463-68-2 | Primary Application: Diabetes research
- Standard Delivery: 2–5 business days
Mechanism of Action
A synthetic GLP-1 receptor agonist with targeted structural modifications ([Aib(8), Arg(34)] + Lys26 C18 fatty acid chain) that resist DPP-4 enzyme degradation and bind tightly to albumin—extending its half-life to ~7 days for sustained activity. It regulates blood glucose by boosting glucose-dependent insulin secretion and suppressing glucagon release, slows gastric emptying, and modulates hypothalamic pathways to reduce appetite and support weight loss.
Key Structural Modifications
~94% homologous to human GLP-1 (7-37), with precision tweaks for enhanced stability and circulation:
- Aib at position 8 (DPP-4 resistance) | Arg at position 34 (improved structural stability)
- C18 fatty acid conjugation at Lys26 (albumin binding, slowed clearance)
- Removal of native GLP-1’s first six amino acids for optimized activity
Primary Research Applications
Type 2 diabetes (glycemic control efficacy); obesity/weight management (appetite regulation); MASH/NASH (metabolic liver fibrosis); cardiometabolic research (hypertension, dyslipidemia, cardiovascular risk); energy metabolism/endocrinology; renal/neuroprotection (diabetic nephropathy, neurodegenerative disease); gut-brain axis signaling (appetite control).
Clinical Reference Formulations
表格
| Formulation | Delivery | Approved Use |
|---|---|---|
| Ozempic® | Weekly injectable | Type 2 diabetes (glycemic control + cardiovascular risk reduction) |
| Rybelsus® | Daily oral tablet | Type 2 diabetes (first oral GLP-1 agonist) |
| Wegovy® | Weekly injectable | Chronic weight management in obese/overweight adults/adolescents |
Advantages Over Other GLP-1 Analogues
Extended ~7-day half-life (enabling once-weekly dosing); superior stability via DPP-4 resistance and strong albumin binding; broad metabolic research potential (beyond diabetes/obesity, covering cardiac, hepatic, renal and neurological pathways).
JPT Peptide Technologies – Quality & Service
German-manufactured research-grade peptides, all HPLC-MS validated for identity and purity; freeze-dried format for maximum stability. Bulk orders available, plus custom peptide synthesis services (tailored sequences, quantities, purity) and conjugation to proteins, nucleic acids or lipids on request. Proven global track record for reliable peptide supply to research institutions worldwide.
Custom Peptide Synthesis
We design and manufacture custom peptide variants to your exact research specifications—including sequence modifications, custom conjugation and bulk production. Enquire for personalized pricing and lead times.
| Contact Channel | Contact Information | |
| +852 54965382 | ||
| Telegram | @Acdcsours | |
| Gmail | allenraws0437@gmail.com |
